BiotechTube

Ro 24-7429

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sarcoma, Kaposi

Conditions

Sarcoma, Kaposi, HIV Infections

Trial Timeline

— → —

NCT ID
NCT00002314

About Ro 24-7429

Ro 24-7429 is a phase 2 stage product being developed by Roche for Sarcoma, Kaposi. The current trial status is completed. This product is registered under clinical trial identifier NCT00002314. Target conditions include Sarcoma, Kaposi, HIV Infections.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00002314Phase 2Completed

Competing Products

20 competing products in Sarcoma, Kaposi

See all competitors
ProductCompanyStageHype Score
Tc99m-tilmanoceptNavidea BiopharmaceuticalsPhase 1
25
Azenosertib + GemcitabineZentalis PharmaceuticalsPhase 1/2
33
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
33
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 1/2
33
AbemaciclibEli LillyPhase 2
52
Abemaciclib + PlaceboEli LillyPhase 3
77
cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acidChugai PharmaceuticalPhase 3
77
PLX3397 + sirolimusDaiichi SankyoPhase 1/2
41
exatecan mesylateDaiichi SankyoPhase 2
52
efatutazoneDaiichi SankyoPhase 2
52
soblidotinDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
LinsitinibAstellas PharmaPhase 2
52
Fluzoparib+ DalpiciclibSun PharmaceuticalPhase 2
52
Anlotinib HydrochlorideSun PharmaceuticalPhase 2
52
Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+VincristineSun PharmaceuticalPhase 2
52
irinotecan liposome (II) + temozolomide + fluzoparibSun PharmaceuticalPhase 2
52
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
77
EribulinEisaiPhase 2
52
Lenvatinib + Ifosfamide + Etoposide + LenvatinibEisaiPhase 2
52

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85